肝动脉灌注化疗在结直肠癌肝转移治疗中的研究进展  

Research progress of hepatic artery infusion chemotherapy in the treatment of colorectal cancer liver metastasis

作　　者：卢欣 罗诗樵[1] LU Xin;LUO Shiqiao(Department of Hepatobiliary Surgery,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,P.R.China)

机构地区：[1]重庆医科大学附属第一医院肝胆外科,重庆400016

出　　处：《中国普外基础与临床杂志》2021年第12期1666-1671,共6页Chinese Journal of Bases and Clinics In General Surgery

摘　　要：目的总结目前肝动脉灌注化疗(HAIC)治疗结直肠癌肝转移(CRLM)的研究进展与临床疗效。方法收集HAIC治疗CRLM的文献并进行综述。结果 CRLM发生率高,影响患者的预后。外科手术是治疗CRLM的首选方式。HAIC可用于术前的新辅助治疗与术后的辅助治疗。结论 HAIC是一种有效的局部治疗CRLM的方式,可作为手术治疗的补充。与系统化疗相比,HAIC联合系统化疗可提高患者的总生存率与无病生存期,降低肝内复发风险,改善患者预后。Objective To summarize the research progress and clinical efficacy of hepatic artery infusion chemotherapy in the treatment of colorectal cancer liver metastasis. Method The literatures of hepatic artery infusion chemotherapy for colorectal cancer liver metastasis were collected and reviewed. Results The incidence of colorectal cancer liver metastasis was high, which affected the prognosis of patients. Surgical treatment was the preferred treatment for colorectal cancer liver metastasis. Hepatic arterial infusion chemotherapy could be used for preoperative neoadjuvant therapy and postoperative adjuvant therapy. Conclusions Hepatic arterial infusion chemotherapy is an effective local treatment for colorectal cancer liver metastasis and can be used as a supplement to surgical treatment. Compared with systemic chemotherapy, hepatic arterial infusion chemotherapy combined with systemic chemotherapy can improve the overall survival and disease-free survival, reduce the risk of intrahepatic recurrence, and improve the prognosis of patients.

关 键 词：结直肠癌肝转移 肝动脉灌注化疗 治疗 综述 

分 类 号：R735.34[医药卫生—肿瘤]